相关实验视频
Updated: Jul 17, 2026

06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
阿尔茨海默病的新型前体粉样蛋白显示出蛋白酶抑制活性
N Kitaguchi1, Y Takahashi, Y Tokushima
1Life Science Research Laboratories, Asahi Chemical Industry Co. Ltd., Shizuoka, Japan.
Nature
|February 11, 1988
概括
研究人员发现了一种具有蛋白酶抑制活性的新型粉样蛋白前体蛋白 (APP). 这一发现可能会揭示阿尔茨海默病中异常的APP处理.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 阿尔茨海默病涉及大脑中的粉样β蛋白 (Aβ) 沉积物.
- 编码粉样前体蛋白 (APP) 的辅助DNA (cDNA) 已经从人类大脑组织中克隆过.
研究的目的:
- 调查APP的新型形式及其潜在功能.
- 探索替代拼接在APP基因表达中的影响.
主要方法:
- 从人类质母细胞瘤细胞系中分离cDNA.
- 隔离cDNA和基因组DNA的测序.
- 用APPcDNA感染COS-1细胞并评估素抑制.
- 在人类大脑中分析信使RNA (mRNA) 物种.
主要成果:
- 发现了一种含有225核酸插入物的新cDNA,与此前报告的APPcDNA不同.
- 插入的推断的氨基酸序列显示了与基本素抑制剂家族的同质性.
- 传染细胞表达较长的APPcDNA表现出增强的素抑制.
- APP基因的替代拼接导致人类大脑中至少有三个不同的mRNA物种.
结论:
- 较长的APP变体具有蛋白酶抑制活性.
- 这种蛋白酶抑制可能与异常的APP代谢有关,可能有助于阿尔茨海默病的病理学.
相关概念视频
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

